Recent News Releases

Onshore mRNA manufacturing will build Australian capability for next generation vaccine technologies Melbourne, Australia: CSL welcomes the Government’s plan to further develop onshore mRNA...

Shareholders agreed to the Board of Directors’ recommendations for all proposed resolutions Election of Dr. Alexandre LeBeaut and Åsa Riisberg as Independent Directors Dividend of CHF 2.00 approved

Etranacogene dezaparvovec (AMT-061) is an investigational gene therapy that may potentially provide people with hemophilia B with years of functional levels of Factor IX, a blood-clotting protein...

KING OF PRUSSIA, PA, USA – MAY 6, 2021 – Global biotherapeutics leader CSL Behring today announced the closing of its global Commercialization and License agreement with uniQure (NASDAQ: QURE) for

Melbourne, Australia: CSL can confirm that production of the AstraZeneca COVID-19 vaccine for Australia has reached more than a million doses a week - these volumes have been produced for a number...

Met primary efficacy endpoint of non-inferiority versus sevelamer carbonate Velphoro® effective in lowering and maintaining serum phosphorus level Safety profile of Velphoro® confirmed...

Topline data expected in the second half of 2021 St. Gallen, Switzerland, and Uniondale, NY, 29 April 2021 – Vifor Pharma and Angion Biomedica Corp. (NASDAQ: ANGN), today announced completion of...

Four Australian Research Programs to be Fast-Tracked in Partnership with CSL Melbourne, Australia: Four Australian medical researcher programs have been awarded a CSL Research Acceleration...

KING OF PRUSSIA, Pa. – April 29, 2021 – Global biotherapeutics leader CSL Behring today announced that the U.S. Food and Drug Administration (FDA) has approved a label update for Hizentra®...

CARE-HK in heart failure (HF) is the first global registry of around 5,000 patients with chronic HF who have or are at high risk for hyperkalemia (HK), in Europe and the US CARE-HK in HF is...